CO5251425A1 - METHOD AND COMPOSITIONS TO ADMINISTER TAXANS ORALLY TO HUMAN PATIENTS - Google Patents

METHOD AND COMPOSITIONS TO ADMINISTER TAXANS ORALLY TO HUMAN PATIENTS

Info

Publication number
CO5251425A1
CO5251425A1 CO00082131A CO00082131A CO5251425A1 CO 5251425 A1 CO5251425 A1 CO 5251425A1 CO 00082131 A CO00082131 A CO 00082131A CO 00082131 A CO00082131 A CO 00082131A CO 5251425 A1 CO5251425 A1 CO 5251425A1
Authority
CO
Colombia
Prior art keywords
taxane
human patients
administered
oral
orally
Prior art date
Application number
CO00082131A
Other languages
Spanish (es)
Inventor
Samuel Brodor
Kenneth Duchin
Selim Sami
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of CO5251425A1 publication Critical patent/CO5251425A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Agentes antineoplásticos de taxano que hasta ahora han exhibido pobre o ninguna biodisponibilidad oral, se administran oralmente a pacientes humanos que sufren de condiciones de enfermedad que responden al taxano y se hace suficientemente biodisponible para alcanzar niveles sanguíneos terapéuticos. En una modalidad preferida, el taxano, preferiblemente paclitaxel, se co-administra al paciente con un agente mejorador de ciclosporina oral, preferiblemente ciclosporina A. Por un método preferido, se administra una dosis de mejorador oral aproximadamente 0.5-72 horas antes del taxano y una segunda dosis del mejorador y se administra inmediatamente antes, junto con o inmediatamente después del taxano. También se provee un método para tratar pacientes humanos que sufren de condiciones de enfermedad con respuesta al taxano, así como un método para proveer tal tratamiento a la vez que se previene o reduce la hipersensibilidad y las reacciones alérgicas sin necesidad de pre-medicación.Taxane antineoplastic agents that have so far exhibited poor or no oral bioavailability, are administered orally to human patients suffering from disease conditions that respond to taxane and becomes bioavailable enough to reach therapeutic blood levels. In a preferred embodiment, the taxane, preferably paclitaxel, is co-administered to the patient with an oral cyclosporine enhancing agent, preferably cyclosporin A. By a preferred method, a dose of oral improver is administered approximately 0.5-72 hours before the taxane and a second dose of the improver and is administered immediately before, together with or immediately after the taxane. A method is also provided to treat human patients suffering from disease conditions with response to taxane, as well as a method to provide such treatment while preventing or reducing hypersensitivity and allergic reactions without the need for pre-medication.

CO00082131A 1999-10-27 2000-10-27 METHOD AND COMPOSITIONS TO ADMINISTER TAXANS ORALLY TO HUMAN PATIENTS CO5251425A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16231099P 1999-10-27 1999-10-27

Publications (1)

Publication Number Publication Date
CO5251425A1 true CO5251425A1 (en) 2003-02-28

Family

ID=22585092

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00082131A CO5251425A1 (en) 1999-10-27 2000-10-27 METHOD AND COMPOSITIONS TO ADMINISTER TAXANS ORALLY TO HUMAN PATIENTS

Country Status (18)

Country Link
EP (1) EP1225956A1 (en)
JP (1) JP2003512443A (en)
KR (1) KR20030019296A (en)
CN (1) CN1450923A (en)
AU (1) AU1104201A (en)
BR (1) BR0015149A (en)
CA (1) CA2389583A1 (en)
CO (1) CO5251425A1 (en)
CZ (1) CZ20021484A3 (en)
HU (1) HUP0203303A3 (en)
IL (1) IL149360A0 (en)
MX (1) MXPA02004164A (en)
NO (1) NO20022008L (en)
PL (1) PL354777A1 (en)
RU (1) RU2002113659A (en)
SK (1) SK5822002A3 (en)
WO (1) WO2001030448A1 (en)
ZA (1) ZA200203358B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750246B1 (en) 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
EP1337273A2 (en) 2000-11-28 2003-08-27 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
AU2003304108B2 (en) * 2002-10-30 2007-03-22 Spherics, Inc. Nanoparticulate bioactive agents
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
PE20060416A1 (en) * 2004-08-03 2006-06-09 Novartis Ag COMPOSITION OF RENIN INHIBITORS AND EFFUSION PROTEIN INHIBITORS
CN101513395B (en) * 2008-02-20 2011-01-12 单宝华 Taxol double-layer soft capsule oral preparation medicament
CA2781529C (en) 2009-09-23 2017-10-24 Indu Javeri Methods for the preparation of liposomes comprising docetaxel
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
EP2566474B1 (en) 2010-05-03 2017-11-15 Teikoku Pharma USA, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
JO3685B1 (en) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc Non-aqueous taxane nanodispersion formulations and methods of using the same
JO3737B1 (en) * 2015-07-21 2021-01-31 Athenex Therapeutics Ltd THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL AND A P-gp INHIBITOR FOR THE TREATMENT OF CANCER
EP4059497A1 (en) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
JP2024512472A (en) * 2021-03-17 2024-03-19 ドムペ・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ C5AR1 inhibitors to treat hypersensitivity reactions to taxanes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2221444A1 (en) * 1996-01-31 1997-08-07 Steven B. Hansel A method of making pharmaceutically active taxanes orally bioavailable
AU3486297A (en) * 1996-06-17 1998-01-07 Eli Lilly And Company Drug resistance and multidrug resistance modulators
KR100615783B1 (en) * 1997-05-27 2006-08-25 아이박스 리서치 인코포레이티드 Method of reducing hypersensitivity or allergic reactions in a mammal except a human body undergoing taxane therapy and pharmaceutical kit
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
IL138767A0 (en) * 1998-04-01 2001-10-31 Rtp Pharma Inc Anticancer compositions
WO2000071079A2 (en) * 1999-05-21 2000-11-30 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Also Published As

Publication number Publication date
CZ20021484A3 (en) 2003-12-17
AU1104201A (en) 2001-05-08
JP2003512443A (en) 2003-04-02
ZA200203358B (en) 2003-04-29
KR20030019296A (en) 2003-03-06
PL354777A1 (en) 2004-02-23
NO20022008D0 (en) 2002-04-26
HUP0203303A3 (en) 2005-01-28
NO20022008L (en) 2002-06-19
EP1225956A1 (en) 2002-07-31
HUP0203303A2 (en) 2003-02-28
CA2389583A1 (en) 2001-05-03
RU2002113659A (en) 2004-01-27
WO2001030448A1 (en) 2001-05-03
SK5822002A3 (en) 2003-01-09
IL149360A0 (en) 2002-11-10
MXPA02004164A (en) 2002-10-17
CN1450923A (en) 2003-10-22
BR0015149A (en) 2002-10-29

Similar Documents

Publication Publication Date Title
CO5251425A1 (en) METHOD AND COMPOSITIONS TO ADMINISTER TAXANS ORALLY TO HUMAN PATIENTS
NO20014519D0 (en) Apomorphine and Sildenafil Preparation
MXPA05006940A (en) Therapeutic formulations for the treatment of beta-amyloid related diseases.
RU2012106620A (en) COMBINATIONS AND METHODS OF INTRODUCING THERAPEUTIC MEDICINES AND COMBINED THERAPY
RU2007138867A (en) TRANS-CLOMIPHENE DOSAGE MODES
RU2007119545A (en) PEGLIATED LIPOSOMAL DOXORUBICIN IN COMBINATION WITH ECTEINASCIDIN 743 (ECTEINESCIDIN 743)
AR048318A1 (en) ORAL MATRIX FORMULATIONS THAT INCLUDE LICARBAZEPINA
BR9809694A (en) Process and composition for administering taxanes orally to human patients
DE50203456D1 (en) DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICAMENTS CONTAINING SUCH COMPOUNDS
HK1077215A1 (en) A pharmaceutical composition for treatment of acute myocardial infarction
AR045263A1 (en) METHOD, KIT AND PHARMACEUTICAL COMPOSITION TO TREAT VIRAL INFECTIONS
BRPI0414518A (en) pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d and parathyroid hormone derivatives
RU2005131578A (en) APLIDINE FOR TREATMENT OF MULTIPLE MYELOMA
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
PT1251850E (en) USE OF A PREPARATION OF COMBINATION IN CANCER THERAPY
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
CA2368352A1 (en) Method for treating neurodegeneration
TW200501967A (en) Nemorubicin for use in the preparation of a medicament for liver disease
NZ516026A (en) Oral administration of taxanes to human patients using cyclosporins as bioavailability-enhancing agents
Susman Relapsed Mantle Cell Lymphoma: Thalidomide Adds to Rituximab's Potency
RU2002113978A (en) A method of stimulating motor activity of the intestine
RU2003124971A (en) METHOD FOR TREATING PATIENTS WITH NEUROTIC AND SOMATOFORM DISORDERS
DK1265629T3 (en) Use of growth hormone in low dose
RU2006138043A (en) METHOD FOR TREATING A STROKE USING DEFIBRINOGENIZING AGENTS TO ACHIEVE THE SPECIFIC CHARACTER OF DEFIBRINOGENIZATION
Kamimura et al. Drug therapy for depression in Japan

Legal Events

Date Code Title Description
FC Application refused